MAP2 and ovarian cancer: When pathogenic variants of TP53, FAT3, RYR2, and somatic variants of MAP2, FAT3, RYR2, CDH11, MAP2, DNAH10, DYNC1H1, and so forth, is found in breast or ovarian cancer, it is inferred to be the putative driver mutations of carcinogenesis.